Historical record - last NADAC effective date: 6/19/2024
Product Information
CHILD MUCINEX MULTI-SYMPTOM LQ is a brand product labeled by RB Health (US) LLC, priced at $0.0704 per ML under NDC 63824094901. Its NADAC has been published 62 times since Jul 21, 2021.
CHILD MUCINEX MULTI-SYMPTOM LQ
Dextromethorphan Hydrobromide, Guaifenesin, and Phenylephrine HydrochlorideStrength
5; 100; 2.5 mg/5mL; mg/5mL; mg/5mL
Manufacturer
RB Health (US) LLCNDC
63824094901
Classification
Brand
Dosage Form
SUSPENSION
Route
ORAL
Effective Date
6/19/2024
Active Ingredients
DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN; PHENYLEPHRINE HYDROCHLORIDEApproval Type
OTC MONOGRAPH DRUG
FDA Application
M012On Market Since
3/30/2018
Pharmacological Classes
Price Statistics
The NADAC for CHILD MUCINEX MULTI-SYMPTOM LQ has been published 62 times since Jul 21, 2021, and over the history we have for it it has risen 14.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0704 per ML |
|---|---|
| All-time high | $0.0716 (May 15, 2024) |
| All-time low | $0.0615 (Jul 21, 2021) |
| Median price | $0.0626 |
| Average price | $0.0655 |
| Largest weekly change | +11.8% (Apr 6, 2022) |
| Weeks tracked | 62 |
| Tracking since | Jul 21, 2021 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
+0.6%
5Y
+14.6%
All
+14.6%
Last surveyed Jul 3, 2024 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Dextromethorphan Hydrobromide, Guaifenesin, and Phenylephrine Hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
RB Health (US) LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Dextromethorphan Hydrobromide, Guaifenesin, and Phenylephrine Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Expectorant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CHILD MUCINEX MULTI-SYMPTOM LQ?
The current National Average Drug Acquisition Cost (NADAC) for CHILD MUCINEX MULTI-SYMPTOM LQ, manufactured by RB Health (US) LLC, is $0.0704 per ML (NDC 63824094901), effective Jul 3, 2024.
How has the price of CHILD MUCINEX MULTI-SYMPTOM LQ changed over time?
Over the history we have for it, the NADAC for CHILD MUCINEX MULTI-SYMPTOM LQ has risen 14.6%. It has been tracked across 62 weekly CMS publications since Jul 21, 2021.
What are the highest and lowest recorded NADAC prices for CHILD MUCINEX MULTI-SYMPTOM LQ?
Since Jul 21, 2021, the NADAC for CHILD MUCINEX MULTI-SYMPTOM LQ has ranged from a low of $0.0615 (Jul 21, 2021) to a high of $0.0716 (May 15, 2024), with a median of $0.0626 per ML.
Are there cheaper alternatives to CHILD MUCINEX MULTI-SYMPTOM LQ?
No other NADAC-published product currently shares the active ingredient and strength of CHILD MUCINEX MULTI-SYMPTOM LQ in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures CHILD MUCINEX MULTI-SYMPTOM LQ?
CHILD MUCINEX MULTI-SYMPTOM LQ (NDC 63824094901) is labeled by RB Health (US) LLC, and CMS classifies it as a brand product.